Biotech Values

[DewDiligence]

TGTX -18% on (belated) clinical-hold disclosure:

https://www.sec.gov/ix?doc=/Archives/edgar/data/0001001316/000155837022000487/tgtx-20220127x8k.htm

On January 27, 2022, TG Therapeutics, Inc. participated in a webcast fireside chat during the B. Riley Securities’ 2022 Virtual Oncology Investor Conference. During the webcast, Michael S. Weiss, Chief Executive Officer of the Company, shared a data and regulatory update. Mr. Weiss noted that the Company was nearing completion of a submission to the U.S. Food and Drug Administration (FDA) of updated Overall Survival (OS) analyses from the UNITY-CLL Phase 3 study evaluating the investigational U2 combination (UKONIQ (umbralisib) and ublituximab) compared to the control arm of obinutuzumab plus chlorambucil and that the FDA imposed a partial clinical hold on select studies of U2 and its components for chronic lymphocytic leukemia (CLL) and non-Hodgkin's lymphoma (NHL).

No press release.